biostudies-literatureUnknown23(1)Junqueira DRTakeda Pharmaceuticals U.S.A.<h4>Background</h4>Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis.<h4>Methods</h4>We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI).<h4>Results</h4>We identified 28 studies assessing AEs experienced by patients treated for gastropDrugs in R&D1-20https://www.ebi.ac.uk/biostudies/studies/S-EPMC9985532biostudies-literatureRisk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.PMC9985532Betts MJunqueira DRBennett DHuh SYFahrbach KNeupane BfalseRisk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis.<h4>Background</h4>Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of dopamine antagonists used in the treatment of children and adults with gastroparesis.<h4>Methods</h4>We searched EMBASE and MEDLINE up to March 25, 2021, for relevant clinical trials and observational studies. We conducted a proportional meta-analysis to estimate the pooled occurrence of AEs (%), with 95% confidence interval (CI), from arm-level data across studies and the comparative occurrence of AEs from placebo-controlled clinical trials (odds ratio [OR] with 95% CI).<h4>Results</h4>We identified 28 studies assessing AEs experienced by patients treated for gastrop2023-01-01T00:00:00Z2023 Mar2026-03-17T15:23:43.418Z2025-02-18T23:35:26.017ZS-EPMC99855323674952810.1007/s40268-023-00413-x